RecruitingNot Applicable

Hepatic Safety of Statin Use in Neurology Inpatients

China2,000 participantsStarted 2024-08-10

Plain-language summary

This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
✓. Age ≥18 and ≤85 years old, both sexes.
✓. Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.

Exclusion criteria

✕. Incomplete medical history.
✕. 1 days ≤ patients with \< 7 days of prior statin use.
✕. Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).

What they're measuring

Aspartate aminotransferase(AST)

Timeframe: 4weeks after admission.

Alanine aminotransferase(ALT)

Timeframe: 4 weeks taken after admission.

Trial details

NCT IDNCT06592196

SponsorShanghai Yueyang Integrated Medicine Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-10

View on ClinicalTrials.gov More Statin Adverse Reaction trials